Pionyr Immunotherapeutics, South San Francisco, CA, United States.
Department of Pathology, University of California, San Francisco, San Francisco, CA, United States.
Front Immunol. 2019 Jul 25;10:1611. doi: 10.3389/fimmu.2019.01611. eCollection 2019.
The tumor microenvironment (TME) of diverse cancer types is often characterized by high levels of infiltrating myeloid cells including monocytes, macrophages, dendritic cells, and granulocytes. These cells perform a variety of functions in the TME, varying from immune suppressive to immune stimulatory roles. In this review, we summarize the different myeloid cell populations in the TME and the intratumoral myeloid targeting approaches that are being clinically investigated, and discuss strategies that identify new myeloid subpopulations within the TME. The TME therapies include agents that modulate the functional activities of myeloid populations, that impact recruitment and survival of myeloid subpopulations, and that functionally reprogram or activate myeloid populations. We discuss the benefits, limitations and potential side effects of these therapeutic approaches.
不同癌症类型的肿瘤微环境（TME）通常具有高水平的浸润性髓系细胞，包括单核细胞、巨噬细胞、树突状细胞和粒细胞。这些细胞在 TME 中发挥多种功能，从免疫抑制作用到免疫刺激作用。在这篇综述中，我们总结了 TME 中的不同髓系细胞群以及正在临床研究的肿瘤内髓系靶向方法，并讨论了识别 TME 中新型髓系亚群的策略。TME 疗法包括调节髓系细胞功能活性的药物、影响髓系亚群募集和存活的药物，以及功能上重新编程或激活髓系细胞的药物。我们讨论了这些治疗方法的益处、局限性和潜在副作用。
